Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Benzinga Newsdesk www.benzinga.com Positive 88.5%

Neg 0% Neu 0% Pos 88.5%

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.